The molecular aspects of personalized anticancer treatment; AIP Conference Proceedings; Vol. 1760 : Physics of Cancer: Interdisciplinary Problems and Clinical Applications 2016

Podrobná bibliografie
Parent link:AIP Conference Proceedings
Vol. 1760 : Physics of Cancer: Interdisciplinary Problems and Clinical Applications 2016.— 2016.— [020010, 5 p.]
Korporativní autor: Национальный исследовательский Томский политехнический университет (ТПУ) Институт кибернетики (ИК) Кафедра оптимизации систем управления (ОСУ)
Další autoři: Cherdyntseva N., Litviakov N., Ivanova F., Denisov E., Gervas P., Cherdyntsev E. S. Evgeny Sergeevich
Shrnutí:Title screen
Only 25% of cancer patients, on average, benefit from therapy. Even in the cases of complete clinical response the tumor progression is an event of high level expectation. The main reasons for tumor progression are: intratumor heterogeneity resulted from clonal evolution, drug resistance, and tumor-promoting microenvironment. The reprogramming of microenvironmental stromal-inflammatory components is expected to allow tumor phenotype reversion. So, to find the new effective markers of tumor progression, drug response and targets for therapy, it could be promising to take into account the tumor-microenvironment heterogeneity and tumor clonal evolution.
Режим доступа: по договору с организацией-держателем ресурса
Jazyk:angličtina
Vydáno: 2016
Témata:
On-line přístup:http://dx.doi.org/10.1063/1.4960229
http://earchive.tpu.ru/handle/11683/35803
Médium: Elektronický zdroj Kapitola
KOHA link:https://koha.lib.tpu.ru/cgi-bin/koha/opac-detail.pl?biblionumber=651979
Popis
Shrnutí:Title screen
Only 25% of cancer patients, on average, benefit from therapy. Even in the cases of complete clinical response the tumor progression is an event of high level expectation. The main reasons for tumor progression are: intratumor heterogeneity resulted from clonal evolution, drug resistance, and tumor-promoting microenvironment. The reprogramming of microenvironmental stromal-inflammatory components is expected to allow tumor phenotype reversion. So, to find the new effective markers of tumor progression, drug response and targets for therapy, it could be promising to take into account the tumor-microenvironment heterogeneity and tumor clonal evolution.
Режим доступа: по договору с организацией-держателем ресурса
DOI:10.1063/1.4960229